Table 3.
Projected complete prevalence (cases) at January 1, 2020 by sex and 10-year variations in Italy
| Prevalent cases | Variation (%) | |||||
|---|---|---|---|---|---|---|
| 2020 | 10-year period | |||||
| Cancer Typea | Men | Women | Total | Men | Women | Total |
| All types but skin non-melanoma | 1687,049 | 1,922,086 | 3,609,135 | 41.3% | 33.1% | 36.8% |
| Upper aero-digestive tract | 36,081 | 21,831 | 57,911 | 34.9% | 41.5% | 37.3% |
| Stomach | 50,327 | 32,033 | 82,360 | 9.5% | −9.9% | 1.0% |
| Colon, Rectum, Anus | 280,277 | 233,245 | 513,522 | 51.1% | 35.7% | 43.7% |
| Liver | 25,234 | 8531 | 33,765 | 44.6% | 16.4% | 36.2% |
| Larynx | 47,015 | 6006 | 53,020 | 4.9% | 36.3% | 7.7% |
| Lung | 77,159 | 40,657 | 117,816 | 22.4% | 71.4% | 35.8% |
| Skin Melanoma | 80,069 | 89,831 | 169,900 | 78.0% | 56.2% | 65.8% |
| Connective Tissue | 17,040 | 11,815 | 28,855 | 44.9% | 19.1% | 33.1% |
| Female Breast | 834,154 | 834,154 | 37.9% | 37.9% | ||
| Cervix Uteri | 51,136 | 51,136 | −13.2% | −13.2% | ||
| Corpus Uteri (endometrium) | 122,553 | 122,553 | 18.6% | 18.6% | ||
| Ovary | 49,807 | 49,807 | 9.2% | 9.2% | ||
| Prostate | 563,960 | 563,960 | 84.9% | 84.9% | ||
| Testis | 63,395 | 63,395 | 67.1% | 67.1% | ||
| Kidney | 97,249 | 47,151 | 144,400 | 54.8% | 33.8% | 47.2% |
| Bladder | 255,015 | 58,608 | 313,624 | 32.4% | 22.6% | 30.4% |
| Brain and central nervous system | 23,505 | 29,314 | 52,819 | 45.9% | 26.7% | 34.6% |
| Thyroid | 45,949 | 166,914 | 212,863 | 80.1% | 78.8% | 79.1% |
| Hodgkin Lymphoma | 37,692 | 29,314 | 67,006 | 35.5% | 43.5% | 38.9% |
| Non- Hodgkin Lymphoma | 82,780 | 73,584 | 156,364 | 45.7% | 36.5% | 41.2% |
| Leukaemias | 45,880 | 39,100 | 84,980 | 27.1% | 25.3% | 26.3% |
| Multiple Myeloma | 19,472 | 17,159 | 36,631 | 52.3% | 39.8% | 46.1% |
a Cancer types with more than 20,000 prevalent cases at 2010